SRR1375952
GTEX
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- GTEX
- cancer_type_detailed
- —
- subtype
- —
- cancer_type
- GTEX
- sex
- Male
GSVA pathway preview (0 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR665670 | GTEX | — | 0.873 |
| 2 | SRR1329835 | GTEX | — | 0.873 |
| 3 | SRR1362777 | GTEX | — | 0.867 |
| 4 | SRR1355373 | GTEX | — | 0.865 |
| 5 | SRR1470212 | GTEX | — | 0.862 |
| 6 | SRR1396659 | GTEX | — | 0.858 |
| 7 | SRR608598 | GTEX | — | 0.858 |
| 8 | SRR1329551 | GTEX | — | 0.856 |
| 9 | SRR1470035 | GTEX | — | 0.855 |
| 10 | SRR1430248 | GTEX | — | 0.855 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 19 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.503 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.383 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.379 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.275 | Inavolisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.266 | Idelalisib | — uncovered |
| KRAS_SIGNALING_DN | 0.223 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_UP | 0.216 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.168 | Inavolisib | — uncovered |
| COAGULATION | 0.160 | Binimetinib | — uncovered |
| COMPLEMENT | 0.146 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.121 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.100 | Temsirolimus | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.085 | Inavolisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.070 | Idelalisib | — uncovered |
| APOPTOSIS | 0.065 | Idelalisib | — uncovered |
| MYOGENESIS | 0.042 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.040 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.029 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.006 | Inavolisib | — uncovered |